Literature DB >> 16339154

Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates.

Yu Tian1, Istvan Sohar, John W Taylor, Peter Lobel.   

Abstract

Classical late-infantile neuronal ceroid lipofuscinosis is a fatal neurodegenerative disease caused by mutations in CLN2, the gene encoding the lysosomal protease tripeptidyl-peptidase I (TPP I). The natural substrates for TPP I and the pathophysiological processes associated with lysosomal storage and disease progression are not well understood. Detailed characterization of TPP I substrate specificity should provide insights into these issues and also aid in the development of improved clinical and biochemical assays. To this end, we constructed fluorogenic and standard combinatorial peptide libraries and analyzed them using fluorescence and mass spectrometry-based activity assays. The fluorogenic group 7-amino-4-carbamoylmethylcoumarin was incorporated into a series of 7-amino-4-carbamoylmethylcoumarin tripeptide libraries using a design strategy that allowed systematic evaluation of the P1, P2, and P3 positions. TPP I digestion of these substrates liberates the fluorescence group and results in a large increase in fluorescence that can be used to calculate kinetic parameters and to derive the substrate specificity constant kcat/KM. In addition, we implemented a mass spectrometry-based assay to measure the hydrolysis of individual peptides in peptide pools and thus expand the scope of the analysis. Nonfluorogenic tetrapeptide and pentapeptide libraries were synthesized and analyzed to evaluate P1' and P2' residues. Together, this analysis allowed us to predict the relative specificity of TPP I toward a wide range of potential biological substrates. In addition, we evaluated a variety of new fluorogenic peptides with a P3 Arg residue, and we demonstrated their superiority compared with the widely used substrate Ala-Ala-Phe-AMC for selectively measuring TPP I activity in biological specimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339154     DOI: 10.1074/jbc.M507336200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  Using specificity to strategically target proteases.

Authors:  Mark D Lim; Charles S Craik
Journal:  Bioorg Med Chem       Date:  2008-03-30       Impact factor: 3.641

2.  Multiplex Tandem Mass Spectrometry Enzymatic Activity Assay for Newborn Screening of the Mucopolysaccharidoses and Type 2 Neuronal Ceroid Lipofuscinosis.

Authors:  Yang Liu; Fan Yi; Arun Babu Kumar; Naveen Kumar Chennamaneni; Xinying Hong; C Ronald Scott; Michael H Gelb; Frantisek Turecek
Journal:  Clin Chem       Date:  2017-04-20       Impact factor: 8.327

3.  Intravitreal Implantation of Genetically Modified Autologous Bone Marrow-Derived Stem Cells for Treating Retinal Disorders.

Authors:  Christopher J Tracy; Douglas N Sanders; Jeffrey N Bryan; Cheryl A Jensen; Leilani J Castaner; Mark D Kirk; Martin L Katz
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  Glial fibrillary acidic protein is elevated in the lysosomal storage disease classical late-infantile neuronal ceroid lipofuscinosis, but is not a component of the storage material.

Authors:  Su Xu; David E Sleat; Michel Jadot; Peter Lobel
Journal:  Biochem J       Date:  2010-05-27       Impact factor: 3.857

5.  Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis.

Authors:  David E Sleat; Mukarram El-Banna; Istvan Sohar; Kwi-Hye Kim; Kostantin Dobrenis; Steven U Walkley; Peter Lobel
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

6.  A critical tryptophan and Ca2+ in activation and catalysis of TPPI, the enzyme deficient in classic late-infantile neuronal ceroid lipofuscinosis.

Authors:  Salomon Kuizon; Kathleen DiMaiuta; Marius Walus; Edmund C Jenkins; Marisol Kuizon; Elizabeth Kida; Adam A Golabek; Daniel O Espinoza; Raju K Pullarkat; Mohammed A Junaid
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.752

7.  Lysosomal enzyme tripeptidyl peptidase 1 destabilizes fibrillar Aβ by multiple endoproteolytic cleavages within the β-sheet domain.

Authors:  Santiago Solé-Domènech; Ana V Rojas; Gia G Maisuradze; Harold A Scheraga; Peter Lobel; Frederick R Maxfield
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

8.  Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis.

Authors:  Kwi-Hye Kim; Christine T Pham; David E Sleat; Peter Lobel
Journal:  Biochem J       Date:  2008-10-15       Impact factor: 3.857

9.  Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.

Authors:  Jayita Guhaniyogi; Istvan Sohar; Kalyan Das; Ann M Stock; Peter Lobel
Journal:  J Biol Chem       Date:  2008-11-26       Impact factor: 5.157

10.  AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.

Authors:  Martin L Katz; Luis Tecedor; Yonghong Chen; Baye G Williamson; Elena Lysenko; Fred A Wininger; Whitney M Young; Gayle C Johnson; Rebecca E H Whiting; Joan R Coates; Beverly L Davidson
Journal:  Sci Transl Med       Date:  2015-11-11       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.